Cost and Cost-effectiveness of Large-scale Screening for Type 1 Diabetes in Colorado.
R Brett McQueenCristy Geno RasmussenKathleen WaughBrigitte I FrohnertAndrea K SteckLiping YuJudith BaxterMarian RewersPublished in: Diabetes care (2020)
Presymptomatic type 1 diabetes screening may be cost-effective in areas with a high prevalence of DKA and an infrastructure facilitating screening and monitoring if the benefits of avoiding DKA events and improved HbA1c persist over long-run time horizons. As more data are collected from ASK, the model will be updated with direct evidence on screening effects.